Veracyte, Inc. (VCYT) News
Filter VCYT News Items
VCYT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VCYT News Highlights
- For VCYT, its 30 day story count is now at 3.
- Over the past 13 days, the trend for VCYT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest VCYT News From Around the Web
Below are the latest news stories about VERACYTE INC that investors may wish to consider to help them evaluate VCYT as an investment opportunity.
Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., December 12, 2023--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will present at the 42nd annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 1:30 p.m. Pacific Time. |
Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to ProgressSOUTH SAN FRANCISCO, Calif., December 01, 2023--Veracyte, Inc. (Nasdaq: VCYT) announced that new data presented today at the 24th Annual Meeting of the Society of Urologic Oncology (SUO 2023) highlight clinical observations and translational research conducted by users of the company’s Decipher Prostate Genomic Classifier. These independent, real-world studies provide further evidence supporting the clinical utility of the test in the treatment and management of prostate cancer, particularly for |
Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung NodulesSOUTH SAN FRANCISCO, Calif., November 29, 2023--Clinical Validation Data for Veracyte's Percepta Nasal Swab Test Published in CHEST |
Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023SOUTH SAN FRANCISCO, Calif., November 22, 2023--Veracyte, Inc. (Nasdaq: VCYT) today announced that seven posters will be presented at the 24th Annual Meeting of the Society of Urologic Oncology (SUO 2023), where they will demonstrate the clinical performance of Veracyte’s Decipher Prostate Genomic Classifier in identifying patients whose prostate cancer is likely to progress and require treatment. Collectively, the posters will report data from more than 60,000 patients. The meeting will take pl |
Veracyte, Inc. (NASDAQ:VCYT) Q3 2023 Earnings Call TranscriptVeracyte, Inc. (NASDAQ:VCYT) Q3 2023 Earnings Call Transcript November 7, 2023 Veracyte, Inc. misses on earnings expectations. Reported EPS is $-0.41 EPS, expectations were $-0.16. Operator: Good day, and thank you for standing by. Welcome to the Veracyte Third Quarter 2023 Financial Results Webcast. At this time all participants are in a listen-only mode. [Operator […] |
Veracyte Announces Third Quarter 2023 Financial ResultsSOUTH SAN FRANCISCO, Calif., November 07, 2023--Veracyte Announces Third Quarter 2023 Financial Results. |
Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients GloballySOUTH SAN FRANCISCO, Calif., November 07, 2023--Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally |
Veracyte to Participate in the Stephens Annual Investment ConferenceSOUTH SAN FRANCISCO, Calif., November 02, 2023--Veracyte, Inc. (Nasdaq: VCYT) announced today that Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Stephens Annual Investment Conference on Wednesday, November 15, at 3:00 p.m. Eastern Time. |
Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug DevelopmentSOUTH SAN FRANCISCO, Calif., October 27, 2023--Veracyte, Inc. (Nasdaq: VCYT) today announced that two poster presentations taking place at SITC 2023, the annual meeting of the Society for Immunotherapy of Cancer, in San Diego from November 3-5 will demonstrate the potential for using the company’s novel tools to help advance the development of immuno-oncology drugs. These tools allow for better characterization of the tumor microenvironment (TME), which can enable new insights into drug response |
7 Undervalued Stocks That Analysts Love Right NowAhead of possible volatility in the market, investors may find some measure of confidence in undervalued stocks. |